GlassScriptPhysician profile
Michael Jerome Kaempf
NPI 1194712182
$269.51
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $89.76 · 2022: $30.98.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $62.67 | 2019 | |
| Karl Storz Endoscopy-America | $44.43 | 2020 | |
| Astellas Pharma US INC | $38.58 | 2019 | |
| Janssen Biotech, INC. | $31.46 | 2019 | |
| Dendreon Pharmaceuticals LLC | $28.64 | 2020 | |
| Coloplast Corp | $24.32 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $18.54 | 2022 | |
| Dornier Medtech America, INC | $16.69 | 2020 | |
| Travere Therapeutics, INC. | $4.18 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kaempf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.